| http://www.w3.org/ns/prov#value | - These risks include: inability to successfully arrange development agreements, particularly for AZX100; delays in obtaining or inability to obtain FDA, institutional review board or other regulatory approvals of pre-clinical or clinical testing; unfavorable outcomes in pre-clinical and clinical testing; the development by others of competing technologies and therapeutics that may have greater effi
|
